A Pilot Trial of Dextroamphetamine for Methamphetamine Dependence
NCT ID: NCT00630682
Last Updated: 2013-06-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
60 participants
INTERVENTIONAL
2006-09-30
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction
NCT00571922
Methylphenidate to Treat Methamphetamine Dependence
NCT01044238
Studying Amphetamine Withdrawal in Humans
NCT01215929
Pilot Study Examining Effect for Dextroamphetamine to Treat Cocaine Dependence Plus Attention-deficit Hyperactivity Disorder (ADHD)
NCT00514202
Prometa Pharmacotherapy for Methamphetamine Dependence
NCT00260481
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dextroamphetamine
Active drug
Dextroamphetamine
1 week placebo and 8 weeks 60mg d-AMP QD.
Placebo
Placebo of drug
Placebo
9 weeks of placebo 60mg capsules QD.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dextroamphetamine
1 week placebo and 8 weeks 60mg d-AMP QD.
Placebo
9 weeks of placebo 60mg capsules QD.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Contact site for additional information
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
California Pacific Medical Center Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gantt Galloway, PharmD
Scientist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gantt Galloway, PharmD
Role: PRINCIPAL_INVESTIGATOR
Addiction Pharmacology Research Laboratory
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CPMC-St. Luke's Campus-Addiction Pharmacology Research Laboratory
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
25.139
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.